MX2020013509A - Composiciones y métodos para la modificación postraduccional in vivo. - Google Patents

Composiciones y métodos para la modificación postraduccional in vivo.

Info

Publication number
MX2020013509A
MX2020013509A MX2020013509A MX2020013509A MX2020013509A MX 2020013509 A MX2020013509 A MX 2020013509A MX 2020013509 A MX2020013509 A MX 2020013509A MX 2020013509 A MX2020013509 A MX 2020013509A MX 2020013509 A MX2020013509 A MX 2020013509A
Authority
MX
Mexico
Prior art keywords
translational modification
protein
compositions
methods
subject
Prior art date
Application number
MX2020013509A
Other languages
English (en)
Inventor
David Weiner
Megan Wise
Ziyang Xu
Original Assignee
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst filed Critical Wistar Inst
Publication of MX2020013509A publication Critical patent/MX2020013509A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
    • C12Y208/02—Sulfotransferases (2.8.2)
    • C12Y208/0202—Protein-tyrosine sulfotransferase (2.8.2.20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona métodos para modificar postraduccionalmente una proteína sintética en un sujeto; en una modalidad, el método comprende administrar al sujeto una composición que comprende una primera secuencia de ácido nucleico recombinante que codifica la proteína sintética y una segunda secuencia de ácido nucleico recombinante que codifica una proteína modificadora, en donde la proteína modificadora modifica postraduccionalmente el producto biológico sintético en el sujeto; en una modalidad, la modificación postraduccional es la sulfatación y la proteína modificadora se selecciona del grupo que consiste en tirosilproteína sulfotransferasa 1 (TPST1) y TPST2.
MX2020013509A 2018-06-11 2019-06-11 Composiciones y métodos para la modificación postraduccional in vivo. MX2020013509A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862683344P 2018-06-11 2018-06-11
PCT/US2019/036470 WO2019241193A1 (en) 2018-06-11 2019-06-11 Compositions and methods for in vivo post translational modification

Publications (1)

Publication Number Publication Date
MX2020013509A true MX2020013509A (es) 2021-05-12

Family

ID=68843598

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013509A MX2020013509A (es) 2018-06-11 2019-06-11 Composiciones y métodos para la modificación postraduccional in vivo.

Country Status (12)

Country Link
US (1) US20210244795A1 (es)
EP (1) EP3801636A4 (es)
JP (1) JP2021527080A (es)
KR (1) KR20210021008A (es)
CN (1) CN112584870A (es)
AU (1) AU2019284482A1 (es)
BR (1) BR112020025249A2 (es)
CA (1) CA3103097A1 (es)
EA (1) EA202092934A1 (es)
MX (1) MX2020013509A (es)
SG (1) SG11202012362SA (es)
WO (1) WO2019241193A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116554356B (zh) * 2023-05-16 2024-01-23 武汉大学 一种hyperIL-15与sCD4及Fc的融合蛋白及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713283B2 (en) * 1998-01-29 2004-03-30 The Board Of Regents Of The University Of Oklahoma Tyrosylprotein sulfotransferases
CA2332563A1 (en) * 1998-06-16 1999-12-23 The Board Of Regents Of The University Of Oklahoma Glycosulfopeptides and methods of synthesis and use thereof
US7265085B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
WO2005118874A1 (en) * 2004-06-04 2005-12-15 Wyeth Enhancing protein expression
CA2964234A1 (en) * 2014-10-10 2016-04-14 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules in vitro and in vivo
EP3274368A1 (en) * 2015-03-25 2018-01-31 THE UNITED STATES OF AMERICA, represented by the S Bispecific multivalent fusion proteins
US10626161B2 (en) * 2015-04-28 2020-04-21 The Scripps Research Institute Methods and compositions for protection against lentiviral infections

Also Published As

Publication number Publication date
EP3801636A1 (en) 2021-04-14
AU2019284482A1 (en) 2021-01-28
SG11202012362SA (en) 2021-01-28
KR20210021008A (ko) 2021-02-24
CA3103097A1 (en) 2019-12-19
US20210244795A1 (en) 2021-08-12
EP3801636A4 (en) 2022-05-04
JP2021527080A (ja) 2021-10-11
EA202092934A1 (ru) 2021-04-05
CN112584870A (zh) 2021-03-30
WO2019241193A1 (en) 2019-12-19
BR112020025249A2 (pt) 2021-03-09

Similar Documents

Publication Publication Date Title
MX2024003455A (es) Sistemas de represores de casx dise?ados por ingenieria genetica.
ES2054878T3 (es) Expresion de la proapolipoproteina a-i humana.
MX2020010871A (es) Compuestos de 5'-caperuza-trinucleótidos u oligonucleótidos superiores y sus usos en estabilizar arn, que expresan proteínas y en la terapia.
BR112021021912A2 (pt) Nova nuclease omni-50 crispr
ATE540055T1 (de) Zusammensetzungen und verfahren zur herstellung von glykosylierungsmutanten des menschlichen wachstumshormons
BR112021014255A2 (pt) Molécula de ácido nucleico, composição, e, método de prevenção ou tratamento de uma doença ou distúrbio
WO2017053732A3 (en) Composition and method for treating complement-mediated disease
MX2021010039A (es) Novedosas proteinas de fusion especificas para cd137 y gpc3.
MX2022011394A (es) Composiciones y metodos para la induccion de una respuesta inmune.
DK1390504T3 (da) Nikleotidsekvenser, som koder for genet metD
PH12017502213A1 (en) Compositions and methods for treating celiac sprue disease
PH12017502323A1 (en) Novel xylanase
MX2020013509A (es) Composiciones y métodos para la modificación postraduccional in vivo.
BR112022014586A2 (pt) Colágeno dietário não derivado de animais
BR112022011975A2 (pt) Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
NZ601950A (en) Method for producing pyripyropene
KR20180084352A (ko) 돌돔 유래의 신규한 피스시딘 펩티드 및 이의 용도
ZA202110285B (en) Antibodies and methods of use
WO2023130022A3 (en) Cystatin rna compositions for tissue engineering
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.
PE20200385A1 (es) Variantes de proteina morfogenica osea humana 7 (bmp7)
MY202141A (en) Peptide mapping method for sequence identification of insulin & insulin analogues
CO2022004535A2 (es) Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes
AR025482A1 (es) Secuencia de adn que codifica una proteina capaz de ligarse a traf; vector que comprende dicha secuencia; celulas huespedes transformadas con dicho vector;proteinas iren codificadas por dicha secuencia; metodo para producir dicha proteina; anticuerpos especificos para dichas proteinas; metodo para m